{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:02:11Z","timestamp":1791446531667,"version":"4.3.3"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Despite the introduction of new molecular classifications, advanced colorectal cancer (CRC) is treated with chemotherapy supplemented with anti-EGFR and anti-VEGF targeted therapy. In this study, 552 CRC cases with different primary tumor locations (250 left side, 190 rectum, and 112 right side) were retrospectively analyzed by next generation sequencing for mutations in 50 genes. The most frequently mutated genes were\n                    <jats:italic>TP53<\/jats:italic>\n                    in left-sided tumors compared to right-sided tumors and\n                    <jats:italic>BRAF<\/jats:italic>\n                    in right-sided tumors compared to left-sided tumors. Mutations in\n                    <jats:italic>KRAS<\/jats:italic>\n                    ,\n                    <jats:italic>NRAS<\/jats:italic>\n                    , and\n                    <jats:italic>BRAF<\/jats:italic>\n                    were not detected in 45% of patients with left-sided tumors and in 28.6% of patients with right-sided tumors. Liver metastases were more common in patients with left-sided tumors. Tumors on the right side were larger at diagnosis and had a higher grade (G3) than tumors on the left. Rectal tumors exhibit distinctive biological characteristics when compared to left-sided tumors, including a higher absence rate of\n                    <jats:italic>KRAS, NRAS<\/jats:italic>\n                    , and\n                    <jats:italic>BRAF<\/jats:italic>\n                    mutations (47.4% in rectal versus 42.8% in left-sided tumors). These rectal tumors are also unique in their primary metastasis site, which is predominantly the lungs, and they have varying mutation rates, particularly in genes such as\n                    <jats:italic>BRAF<\/jats:italic>\n                    ,\n                    <jats:italic>FBXW7<\/jats:italic>\n                    , and\n                    <jats:italic>TP53<\/jats:italic>\n                    , that distinguish them from tumors found in other locations. Primary tumor location has implications for the potential treatment of CRC with anti-EGFR therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-55139-w","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T05:03:29Z","timestamp":1708923809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients"],"prefix":"10.1038","volume":"14","author":[{"given":"Izabela","family":"Ciepiela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Szczepaniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Ciepiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Hi\u0144cza-Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Kopczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Macek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Kubicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Chrapek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Tyka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanis\u0142aw","family":"G\u00f3\u017ad\u017a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Kowalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"55139_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"55139_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3322\/caac.21601","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L. et al. Colorectal cancer statistics, 2020. CA Cancer J. Clin. 70, 145\u2013164 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"55139_CR3","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer 103, 356\u2013387 (2018).","journal-title":"Eur. J. Cancer"},{"key":"55139_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","volume":"61","author":"ER Fearon","year":"1990","unstructured":"Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759\u2013767 (1990).","journal-title":"Cell"},{"key":"55139_CR5","doi-asserted-by":"publisher","first-page":"15065","DOI":"10.1038\/nrdp.2015.65","volume":"1","author":"EJ Kuipers","year":"2015","unstructured":"Kuipers, E. J. et al. Colorectal cancer. Nat. Rev. Dis. Primers 1, 15065 (2015).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"55139_CR6","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350\u20131356 (2015).","journal-title":"Nat. Med."},{"key":"55139_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrclinonc.2016.171","volume":"14","author":"CJA Punt","year":"2017","unstructured":"Punt, C. J. A., Koopman, M. & Vermeulen, L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat. Rev. Clin. Oncol. 14, 235\u2013246 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"55139_CR8","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem, E. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386\u20131422 (2016).","journal-title":"Ann. Oncol."},{"key":"55139_CR9","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"55139_CR10","doi-asserted-by":"publisher","first-page":"175628482091752","DOI":"10.1177\/1756284820917527","volume":"13","author":"G Golshani","year":"2020","unstructured":"Golshani, G. & Zhang, Y. Advances in immunotherapy for colorectal cancer: A review. Ther. Adv. Gastroenterol. 13, 1756284820917527 (2020).","journal-title":"Ther. Adv. Gastroenterol."},{"key":"55139_CR11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ejso.2014.11.001","volume":"41","author":"GH Lee","year":"2015","unstructured":"Lee, G. H. et al. Is right-sided colon cancer different to left-sided colorectal cancer?\u2014A systematic review. Eur. J. Surg. Oncol. 41, 300\u2013308 (2015).","journal-title":"Eur. J. Surg. Oncol."},{"key":"55139_CR12","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M. & Wallace, M. B. Colorectal cancer. Lancet 394, 1467\u20131480 (2019).","journal-title":"Lancet"},{"key":"55139_CR13","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/cam4.1401","volume":"7","author":"M-Z Qiu","year":"2018","unstructured":"Qiu, M.-Z. et al. Comparison of survival between right-sided and left-sided colon cancer in different situations. Cancer Med. 7, 1141\u20131150 (2018).","journal-title":"Cancer Med."},{"key":"55139_CR14","first-page":"253","volume":"18","author":"DL Hanna","year":"2020","unstructured":"Hanna, D. L. & Lenz, H.-J. How we treat left-sided vs right-sided colon cancer. Clin. Adv. Hematol. Oncol. 18, 253\u2013257 (2020).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"55139_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.14740\/gr1062w","volume":"11","author":"B Baran","year":"2018","unstructured":"Baran, B. et al. Difference between left-sided and right-sided colorectal cancer: A focused review of literature. Gastroenterol. Res. 11, 264\u2013273 (2018).","journal-title":"Gastroenterol. Res."},{"key":"55139_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ccell.2017.12.004","volume":"33","author":"R Yaeger","year":"2018","unstructured":"Yaeger, R. et al. Clinical Sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell 33, 125-136.e3 (2018).","journal-title":"Cancer Cell"},{"key":"55139_CR17","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1080\/15384047.2015.1113356","volume":"16","author":"WS El-Deiry","year":"2015","unstructured":"El-Deiry, W. S. et al. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol. Ther. 16, 1726\u20131737 (2015).","journal-title":"Cancer Biol. Ther."},{"key":"55139_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/jmcb\/mjy075","volume":"11","author":"M Nakayama","year":"2019","unstructured":"Nakayama, M. & Oshima, M. Mutant p53 in colon cancer. J. Mol. Cell Biol. 11, 267\u2013276 (2019).","journal-title":"J. Mol. Cell Biol."},{"key":"55139_CR19","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.3390\/cancers13102296","volume":"13","author":"M Michel","year":"2021","unstructured":"Michel, M., Kaps, L., Maderer, A., Galle, P. R. & Moehler, M. The role of p53 dysfunction in colorectal cancer and its implication for therapy. Cancers (Basel) 13, 2296 (2021).","journal-title":"Cancers (Basel)"},{"key":"55139_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bulcan.2014.12.010","volume":"102","author":"J Netter","year":"2015","unstructured":"Netter, J. et al. Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer. Bull. Cancer 102, 117\u2013125 (2015).","journal-title":"Bull. Cancer"},{"key":"55139_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12943-016-0549-8","volume":"15","author":"V Kovaleva","year":"2016","unstructured":"Kovaleva, V. et al. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing. Mol. Cancer 15, 63 (2016).","journal-title":"Mol. Cancer"},{"key":"55139_CR22","doi-asserted-by":"publisher","first-page":"8065","DOI":"10.1038\/srep08065","volume":"5","author":"C Mao","year":"2015","unstructured":"Mao, C. et al. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci. Rep. 5, 8065 (2015).","journal-title":"Sci. Rep."},{"key":"55139_CR23","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383, 1207\u20131217 (2020).","journal-title":"N. Engl. J. Med."},{"key":"55139_CR24","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"55139_CR25","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio, V. et al. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discov. 10, 1129\u20131139 (2020).","journal-title":"Cancer Discov."},{"key":"55139_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger, R. et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 388, 44\u201354 (2023).","journal-title":"N. Engl. J. Med."},{"key":"55139_CR27","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","volume":"11","author":"N Tanaka","year":"2021","unstructured":"Tanaka, N. et al. Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov. 11, 1913\u20131922 (2021).","journal-title":"Cancer Discov."},{"key":"55139_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/ijc.28955","volume":"136","author":"M Schirripa","year":"2015","unstructured":"Schirripa, M. et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int. J. Cancer 136, 83\u201390 (2015).","journal-title":"Int. J. Cancer"},{"key":"55139_CR29","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","volume":"37","author":"M Dankner","year":"2018","unstructured":"Dankner, M., Rose, A. A. N., Rajkumar, S., Siegel, P. M. & Watson, I. R. Classifying BRAF alterations in cancer: New rational therapeutic strategies for actionable mutations. Oncogene 37, 3183\u20133199 (2018).","journal-title":"Oncogene"},{"key":"55139_CR30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nature23291","volume":"548","author":"Z Yao","year":"2017","unstructured":"Yao, Z. et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 548, 234\u2013238 (2017).","journal-title":"Nature"},{"key":"55139_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.bbrc.2020.07.110","volume":"532","author":"S-H Choi","year":"2020","unstructured":"Choi, S.-H., Shin, I., Kim, N., Nam, Y. & Sim, T. The first small molecules capable of strongly suppressing proliferation of cancer cells harboring BRAF class I\/II\/III mutations. Biochem. Biophys. Res. Commun. 532, 315\u2013320 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"55139_CR32","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1158\/0008-5472.CAN-08-2466","volume":"69","author":"A Sartore-Bianchi","year":"2009","unstructured":"Sartore-Bianchi, A. et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69, 1851\u20131857 (2009).","journal-title":"Cancer Res."},{"key":"55139_CR33","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1093\/annonc\/mdr464","volume":"23","author":"C Mao","year":"2012","unstructured":"Mao, C., Yang, Z. Y., Hu, X. F., Chen, Q. & Tang, J. L. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Ann. Oncol. 23, 1518\u20131525 (2012).","journal-title":"Ann. Oncol."},{"key":"55139_CR34","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.18632\/oncotarget.14012","volume":"8","author":"B Zhao","year":"2017","unstructured":"Zhao, B. et al. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget 8, 3980\u20134000 (2017).","journal-title":"Oncotarget"},{"key":"55139_CR35","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.3390\/ijms22073464","volume":"22","author":"R Mishra","year":"2021","unstructured":"Mishra, R., Patel, H., Alanazi, S., Kilroy, M. K. & Garrett, J. T. PI3K inhibitors in cancer: Clinical implications and adverse effects. Int. J. Mol. Sci. 22, 3464 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"55139_CR36","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","volume":"2","author":"P Castel","year":"2021","unstructured":"Castel, P., Toska, E., Engelman, J. A. & Scaltriti, M. The present and future of PI3K inhibitors for cancer therapy. Nat. Cancer 2, 587\u2013597 (2021).","journal-title":"Nat. Cancer"},{"key":"55139_CR37","doi-asserted-by":"publisher","first-page":"1956173","DOI":"10.1080\/2162402X.2021.1956173","volume":"10","author":"T Ugai","year":"2021","unstructured":"Ugai, T. et al. Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma. Oncoimmunology 10, 1956173 (2021).","journal-title":"Oncoimmunology"},{"key":"55139_CR38","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1158\/1078-0432.CCR-15-1811","volume":"22","author":"IP Silva","year":"2016","unstructured":"Silva, I. P. et al. Identification of a novel pathogenic germline KDR variant in melanoma. Clin. Cancer Res. 22, 2377\u20132385 (2016).","journal-title":"Clin. Cancer Res."},{"key":"55139_CR39","doi-asserted-by":"publisher","first-page":"715","DOI":"10.21873\/cgp.20226","volume":"17","author":"N Zaman","year":"2020","unstructured":"Zaman, N. et al. The KDR (VEGFR-2) genetic polymorphism Q472H and c-KIT polymorphism M541L are associated with more aggressive behaviour in astrocytic gliomas. Cancer Genomics Proteom. 17, 715\u2013727 (2020).","journal-title":"Cancer Genomics Proteom."},{"key":"55139_CR40","doi-asserted-by":"publisher","first-page":"6813","DOI":"10.3390\/ijms22136813","volume":"22","author":"C Guarini","year":"2021","unstructured":"Guarini, C., Grassi, T., Pezzicoli, G. & Porta, C. Beyond RAS and BRAF: HER2, a new actionable oncotarget in advanced colorectal cancer. Int. J. Mol. Sci. 22, 6813 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"55139_CR41","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","volume":"3","author":"R Bose","year":"2013","unstructured":"Bose, R. et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 3, 224\u2013237 (2013).","journal-title":"Cancer Discov."},{"key":"55139_CR42","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1158\/2159-8290.CD-14-1211","volume":"5","author":"SM Kavuri","year":"2015","unstructured":"Kavuri, S. M. et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov. 5, 832\u2013841 (2015).","journal-title":"Cancer Discov."},{"key":"55139_CR43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.clcc.2020.02.007","volume":"19","author":"A De Cuyper","year":"2020","unstructured":"De Cuyper, A., Van Den Eynde, M. & Machiels, J.-P. HER2 as a predictive biomarker and treatment target in colorectal cancer. Clin. Colorectal Cancer 19, 65\u201372 (2020).","journal-title":"Clin. Colorectal Cancer"},{"key":"55139_CR44","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","volume":"3","author":"S Tejpar","year":"2017","unstructured":"Tejpar, S. et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: Retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 3, 194\u2013201 (2017).","journal-title":"JAMA Oncol."},{"key":"55139_CR45","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold, D. et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann. Oncol. 28, 1713\u20131729 (2017).","journal-title":"Ann. Oncol."},{"key":"55139_CR46","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris, V. K. et al. Treatment of metastatic colorectal cancer: ASCO guideline. J. Clin. Oncol. 41, 678\u2013700 (2023).","journal-title":"J. Clin. Oncol."},{"key":"55139_CR47","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"CGA Network","year":"2012","unstructured":"Network, C. G. A. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330\u2013337 (2012).","journal-title":"Nature"},{"key":"55139_CR48","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/bjc.2017.294","volume":"117","author":"S Gollins","year":"2017","unstructured":"Gollins, S. et al. Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: Significance of pre-treatment and post-resection RAS mutations. Br. J. Cancer 117, 1286\u20131294 (2017).","journal-title":"Br. J. Cancer"},{"key":"55139_CR49","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1007\/s00261-019-02051-x","volume":"44","author":"S Mondaca","year":"2019","unstructured":"Mondaca, S. & Yaeger, R. Genetics of rectal cancer and novel therapies: Primer for radiologists. Abdom. Radiol. (NY) 44, 3743\u20133750 (2019).","journal-title":"Abdom. Radiol. (NY)"},{"key":"55139_CR50","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/sj.bjc.6602622","volume":"92","author":"E Lopez-Crapez","year":"2005","unstructured":"Lopez-Crapez, E. et al. p53 status and response to radiotherapy in rectal cancer: A prospective multilevel analysis. Br. J. Cancer 92, 2114\u20132121 (2005).","journal-title":"Br. J. Cancer"},{"key":"55139_CR51","doi-asserted-by":"publisher","first-page":"e45388","DOI":"10.1371\/journal.pone.0045388","volume":"7","author":"M-B Chen","year":"2012","unstructured":"Chen, M.-B. et al. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: A meta-analysis in rectal cancer. PLoS One 7, e45388 (2012).","journal-title":"PLoS One"},{"key":"55139_CR52","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.3390\/cancers13092125","volume":"13","author":"MC Liebl","year":"2021","unstructured":"Liebl, M. C. & Hofmann, T. G. The role of p53 signaling in colorectal cancer. Cancers (Basel) 13, 2125 (2021).","journal-title":"Cancers (Basel)"},{"key":"55139_CR53","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/jhg.2015.71","volume":"60","author":"J Bai","year":"2015","unstructured":"Bai, J. et al. Genetic mutations in human rectal cancers detected by targeted sequencing. J. Hum. Genet. 60, 589\u2013596 (2015).","journal-title":"J. Hum. Genet."},{"key":"55139_CR54","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12943-018-0857-2","volume":"17","author":"C-H Yeh","year":"2018","unstructured":"Yeh, C.-H., Bellon, M. & Nicot, C. FBXW7: A critical tumor suppressor of human cancers. Mol. Cancer 17, 115 (2018).","journal-title":"Mol. Cancer"},{"key":"55139_CR55","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1186\/s12885-015-1752-5","volume":"15","author":"L Lupini","year":"2015","unstructured":"Lupini, L. et al. Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. BMC Cancer 15, 808 (2015).","journal-title":"BMC Cancer"},{"key":"55139_CR56","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1002\/ijc.24879","volume":"126","author":"M Iwatsuki","year":"2010","unstructured":"Iwatsuki, M. et al. Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: Clinical significance. Int. J. Cancer 126, 1828\u20131837 (2010).","journal-title":"Int. J. Cancer"},{"key":"55139_CR57","doi-asserted-by":"publisher","first-page":"9240","DOI":"10.18632\/oncotarget.3284","volume":"6","author":"N Li","year":"2015","unstructured":"Li, N. et al. FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15. Oncotarget 6, 9240\u20139256 (2015).","journal-title":"Oncotarget"},{"key":"55139_CR58","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: Efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747\u20131756 (2018).","journal-title":"Genome Res."},{"key":"55139_CR59","unstructured":"R Core Team (2022). R: The R Project for Statistical Computing. https:\/\/www.r-project.org\/."},{"key":"55139_CR60","unstructured":"RStudio Team (2022). RStudio: Integrated Development Environment for R. RStudio, PBC, Boston, MA. https:\/\/www.r-project.org\/."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55139-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55139-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55139-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T17:12:47Z","timestamp":1709226767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55139-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["55139"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-55139-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2880010\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]},"assertion":[{"value":"30 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4619"}}